Published trials using third-party virus-specific T cells to treat EBV lymphoma
| Activation method . | Patients . | CR or PR . | Failure . | GVHD . | ORR . | References . |
|---|---|---|---|---|---|---|
| LCL-induced | 33 (includes SOT) | 17 | 16 | None | 52% | Haque et al, 200741 |
| 57 | 36 | 18 | None | 63% | Prockop et al, 201542 | |
| 10 (includes SOT) | 8 | 2 | None | 80% | Vickers et al, 201424 | |
| 9 | 6 | 3 | 2 | 67% | Leen et al, 201325 | |
| 4 | 1 | 3 | 1 | 25% | Naik et al, 201643 | |
| Pepmix-induced | 2 | 1 | 1 | None | 50% | Naik et al, 201643 |
| Multimer-selected | 1 | 1 | 0 | None | 100% | Uhlin et al, 201044 |
| Activation method . | Patients . | CR or PR . | Failure . | GVHD . | ORR . | References . |
|---|---|---|---|---|---|---|
| LCL-induced | 33 (includes SOT) | 17 | 16 | None | 52% | Haque et al, 200741 |
| 57 | 36 | 18 | None | 63% | Prockop et al, 201542 | |
| 10 (includes SOT) | 8 | 2 | None | 80% | Vickers et al, 201424 | |
| 9 | 6 | 3 | 2 | 67% | Leen et al, 201325 | |
| 4 | 1 | 3 | 1 | 25% | Naik et al, 201643 | |
| Pepmix-induced | 2 | 1 | 1 | None | 50% | Naik et al, 201643 |
| Multimer-selected | 1 | 1 | 0 | None | 100% | Uhlin et al, 201044 |
LCL, lymphoblastoid cell lines; SOT, post-solid organ transplantation.